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Objective Barth Syndrome (BTHS) is an X-linked multisystem disorder (OMIM 302060) usually diagnosed
in infancy and characterized by cardiac problems [dilated cardiomyopathy (DCM) ± endocardial ﬁbroelastosis
(EFE) ± left ventricular non-compaction (LVNC)], proximal myopathy, feeding problems, growth retardation,
neutropenia, organic aciduria and variable respiratory chain abnormalities. We wished to determine whether
BTHS had a signiﬁcant impact on fetal and perinatal health in a large cohort of family groups originating from
a deﬁned region.
Method Case note review on 19 families originating from the UK and known to the Barth Syndrome Service
of the Bristol Royal Hospital for Children.
Results Details are presented on six kindreds (32%) with genetically and biochemically proven BTHS that
demonstrate a wider phenotype including male fetal loss, stillbirth and severe neonatal illness or death. In
these families, 9 males were stillborn and 14 died as neonates or infants but there were no losses of females.
BTHS was deﬁnitively proven in ﬁve males with fetal onset of DCM ± hydrops/EFE/LVNC.
Conclusion These ﬁndings stress the importance of considering BTHS in the differential diagnosis of
unexplained male hydrops, DCM, EFE, LVNC or pregnancy loss, as well as in neonates with hypoglycemia,
lactic acidosis and idiopathic mitochondrial disease. Copyright  2010 John Wiley & Sons, Ltd.
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INTRODUCTION
Barth Syndrome (BTHS) is an X-linked disease con-
ventionally characterized by dilated cardiomyopathy
(DCM) with endocardial ﬁbroelastosis (EFE), skeletal
(predominantly proximal) myopathy, growth retardation,
neutropenia and organic aciduria [especially excess of
3-methylglutaconic (3-MGC) acid] (Kelley et al., 1991;
Barth et al., 1999; Barth, 2005). It results from mutations
of the gene TAZ (previously termed tafazzin), located at
Xq28, which encodes a highly conserved acyltransferase
(Bione et al., 1996).
*Correspondence to: Dr. C. G. Steward, Royal Hospital for Chil-
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Understanding the pathogenesis of BTHS has so far
remained elusive but one major consequence of deﬁ-
ciency of this enzyme is defective remodelling of phos-
pholipid side chains (Vreken et al., 2000). This results
in deﬁciency of cardiolipin (CL) with four linoleic acid
side chains and relative excess of monolysocardiolipin
(MLCL, with just three side chains), and hence to
a highly abnormal MLCL/CL ratio (Valianpour et al.,
2005; Schlame, 2007). This feature has recently allowed
the development of a highly sensitive and speciﬁc assay
applicable to lymphocytes, platelets, muscle biopsies,
ﬁbroblasts or even single stored neonatal bloodspots
(Kulik et al., 2008).
Although ﬁrst reported in 1983 (Barth et al., 1983),
relatively few children have been diagnosed and still
only 160 unrelated cases are known to the Barth Syn-
drome Foundation genetic database for the disorder
(http://www.barthsyndrome.org/). Barriers to case ascer-
tainment have been that (1) the relatively small increase
in organic acid excretion is easily missed or may
even be absent (Schmidt et al., 2004), (2) neutropenia
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may be intermittent (Barth et al., 1999) or non-existent
(manuscript in preparation), and (3) a viral etiology
f o ra c u t eD C Mi so f t e na s s u m e dw h e nt h i si ss e e n
in combination with neutropenia. The latter misdiagno-
sis is compounded by often remarkable improvements
in the cardiomyopathy with age, conﬁrming a suspi-
cion that the patient has recovered from an acute viral
insult.
However, recent years have seen rapid increases in
the rate of case identiﬁcation, driven by a combination
of the realization of the wide and variable phenotype,
and the introduction of genetic testing and CL assays
(Cantlay et al., 1999; Gonzalez, 2005; Houtkooper
et al., 2009). Features of the disease which are less
well known include: hypertrophic cardiomyopathy, iso-
lated left ventricular non-compaction (LVNC), ventricu-
lar arrhythmia (Bleyl et al., 1997; Ichida et al., 2001;
Chen et al., 2002; Brady et al., 2006; Spencer et al.,
2006), motor delay, poor appetite, fatigue and exer-
cise intolerance, hypoglycemia, lactic acidosis, hyper-
ammonemia and dramatic late catch-up growth after
growth delay throughout childhood (Spencer et al.,
2005; Spencer et al., 2006; Spencer et al., 2007; Yen
et al., 2008).
CL comprises approximately one quarter of all mito-
chondrial phospholipid and this probably explains the
observation of abnormal mitochondrial structure and
minor abnormalities of respiratory chain function assays
in some patients (Neustein et al., 1979; Barth et al.,
1996; Xu et al., 2005; Acehan et al., 2007). BTHS is,
therefore, a unique form of mitochondrial disease where
the membrane structural perturbation due to abnormal
phospholipid composition interferes with the mitochon-
drial function. Patients frequently have profound proxi-
mal myopathy and exercise intolerance (Spencer et al.,
2007). The cardiomyopathy is usually dilated at presen-
tation but can swing between dilated and hypertrophic.
Ventricular arrhythmia may occur, especially during ado-
lescence, and may result in sudden death (Spencer et al.,
2005).
Several previous reports have shown that BTHS can
also cause fetal cardiomyopathy. Two papers (Cardonick
et al., 1997; Brady et al., 2006) have reported families
with strong histories of male DCM or male infant/toddler
death, which was ﬁnally ascribed to BTHS. Fetuses
from each report showed ventricular dysfunction, car-
diomegaly or ascites on ultrasound at 32 to 33 weeks’
gestation. A subsequent pregnancy in one of these fam-
ilies was terminated electively at 18 weeks’ gestation
after chorionic villus biopsy and amniocentesis con-
ﬁrmed an affected male (Brady et al., 2006). Autopsy
even at this early stage of fetal life demonstrated car-
diomegaly, EFE and subendocardial vacuolization of the
myocytes.
These ﬁndings, accompanied by an excess of late
spontaneous abortions and stillbirths of male fetuses in
families attending the BTHS clinics at the Bristol Royal
Hospital for Children, led us to undertake a detailed
analysis of fetal deaths in affected UK families. These
conﬁrm that BTHS is a deﬁnite cause of fetal loss in
some families and raise suspicions that it may cause
miscarriage at all phases of pregnancy.
METHODS
Information on fetal and childhood deaths or cardiac
problems was collated from case note review, clinic
interviews and further information on detailed family
history submitted by parents to the UK Barth Syndrome
Service at the Bristol Royal Hospital for Children. All
families were Caucasian and of UK ancestry. BTHS was
proven biochemically (by assay of MLCL/CL ratio) and
genetically (by TAZ gene sequencing) in at least one
member of each kindred.
RESULTS
Six families taken from 19 unrelated kindreds with
deﬁnitively proven BTHS had histories which included
serious fetal or perinatal problems. Their family trees
are shown in Figure 1. For ease of identiﬁcation, each
family is described with reference to one mother who
is given a unique patient number (UPN). References
to previous families found with the same mutations
as patients described here are drawn from the Barth
Syndrome Foundation genetic database.
In families 1, 2 and 3, severe cardiomyopathy (DCM,
fetal hydrops or EFE) occurred in male fetuses subse-
quently shown to have TAZ mutations. Families 4 and
5 have suspicious histories of male third trimester fetal
loss and/or stillbirth in addition to living boys diagnosed
with BTHS. A proven carrier female in family 6 has had
ﬁve fetal losses at up to 22 weeks’ gestation. In these
families, a total of 9 males were stillborn and 14 died
as neonates or infants but there were no spontaneous
abortions, stillbirths or childhood deaths in females.
Family 1
The index mother’s (UPN1) ﬁrst pregnancy resulted in
spontaneous loss of a stillborn male fetus at 31 weeks’
gestation (birth weight 1.57 kg, approximately 30 weeks
by measurements). His heart (weight 10.5 g) and body
were considered to be anatomically normal, although
extensive maceration and autolysis prevented determi-
nation of the cause of fetal demise. The second preg-
nancy resulted in delivery of a healthy normal female
at term. Ultrasound examination at 31 weeks during a
third pregnancy revealed a hydropic male with poor car-
diac contractility. Delivery was induced at 34 weeks’
gestation because of deteriorating fetal condition (birth
weight 2.9 kg). He required intubation at birth and
inotropic support for poor left ventricular (LV) func-
tion and dilatation, followed by drainage of pleural
effusions and ascites. Following progressive deteriora-
tion, care was withdrawn on day 3 of life. Postmortem
showed biventricular dilatation (most marked on the
left), EFE, mild secondary lung hypoplasia, renal tubu-
lar/cortical and pontosubicular neuronal necrosis. The
thymus was atrophic (2.7 g, expected weight 8 g) with
marked lymphocyte depletion on histology. Cardiac his-
tology demonstrated no features to enable a speciﬁc
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Figure 1—Pedigrees of families highlighting the high rate of late miscarriage and stillbirth
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diagnosis. During a fourth pregnancy, feticide was per-
formed at 31+ weeks after an antenatal diagnosis of
cardiomyopathy and hydrops. At postmortem, the fetus
weighed 2.32 kg with linear measurements equivalent
to 37 weeks’ gestation. There was biventricular cardiac
dilatation with mild diffuse EFE but no focal myocardial
lesions and no vacuolation or other features suggestive
of metabolic disease on histology. The thymus was
atrophic (2.5 g, expected weight 7 g). Skin ﬁbroblasts
grown from the second male showed a highly aberrant
MLCL/CL ratio, and mutation analysis of DNA from the
second and third males revealed a missense mutation in
the TAZ gene (c.280C>G, p.Arg94Gly). This mutation
has been previously reported as causing BTHS, affects
a highly conserved residue, and is identiﬁed occurring
de novo in the mother, providing good evidence for
causation.
Family 2
The index mother’s (UPN2) ﬁrst pregnancy resulted in
an emergency lower segment caesarian section (LSCS)
at term and delivery of a male neonate who required
intubation at delivery. DCM was diagnosed, with an
LV fractional shortening of 10%. Initial neutrophil
count, white cell enzyme assays, serum lactate, amino
acid/organic acid/oligosaccharide analysis were all nor-
mal, although neutropenia developed later. He required a
long period of ventilation and aggressive inotropic sup-
port. Echocardiogram at 3 months suggested LVNC.
In her second pregnancy, cardiac ultrasound was nor-
mal at 22 weeks’ gestation but a male fetus was stillborn
at emergency caesarian section at 37 weeks following
an abnormal cardiotocograph. Birth weight was 2.95 kg
and crown-heel length 47 cm. Postmortem suggested
that death had probably occurred several days prior to
delivery. There were no dysmorphic features although
the ears were large. The heart showed LV myocardial
thickening (8 mm maximum thickness) and LV dilata-
tion but normal right ventricular dimensions. Histol-
ogy demonstrated vacuolated myocytes and biventricular
EFE. T-associated areas of the spleen were reduced and
the cortical thickness of the thymus markedly reduced
with appreciable lymphocyte depletion. A mitochondrial
cytopathy was suspected but further studies were pre-
vented by autolysis of the cardiac tissue.
The cause of DCM in the ﬁrstborn was eventually
shown to be BTHS by demonstration of a highly aberrant
MLCL/CL ratio and demonstration of a c.583+5G>A
mutation in IVS7 of the TAZ gene, a mutation predicted
to lead to aberrant RNA splicing. The same mutation
was subsequently conﬁrmed in tissue from the stillborn
fetus and UPN2 was conﬁrmed as a carrier of the BTHS
mutation. She subsequently had a further miscarriage at
7 weeks’ gestation. The wider family history was also
suspicious: UPN2’s mother had a full-term male who
died at 2 h of age and was said to have had a problem
with his heart valves. Her grandmother had 12 babies
from 11 pregnancies: six healthy girls, two healthy boys,
twin males who were stillborn, a boy who died soon
after birth and a further boy who died after 13 weeks in
hospital.
Family 3
This family has a very extensive history of BTHS due
to a mutation in the TAZ gene (exon 8, c.589G>A,
p.Gly197Arg; a mutation ‘hotspot’ which has been
identiﬁed in several families, is evolutionarily highly
conserved, and segregates with the condition in this
family). UPN3 (a known carrier) gave birth to a male
who developed DCM at 22 weeks’ gestation and who
was delivered by urgent LCSC at 32 weeks due to fetal
distress. Although initially well controlled on inotropes,
he died at 1 week due to cardiac decompensation
triggered by ventricular arrhythmias. Disease expression
in this family has been very variable. A cousin with
BTHS was well until falling behind in achievement of
motor milestones from 1 year. He developed feeding
problems and lethargy at 2.5 years, was diagnosed with
DCM at 3.5 years and required cardiac transplantation
several months later. Another cousin was only diagnosed
with BTHS after the disease had been identiﬁed in
his brother (who developed DCM at 3 months of age,
without accompanying neutropenia); when diagnosed at
3.5 years this boy’s only sign was proximal myopathy.
Another distant relative (previously reported in Ronghe
et al., 2001) died of post-transplant lymphoproliferative
disease 7 years after the cardiac transplantation for
DCM which presented at 6 months. His grandmother
(a proven carrier of the familial TAZ mutation) had six
pregnancies, which resulted in live birth of three normal
females in addition to three male fetal deaths, one each
in the second and third trimesters and one stillborn at
term. Postmortems were not performed on these fetuses.
A distant male relative (whose sister and mother are
proven carriers of the G197R TAZ mutation) died of
DCM with EFE at 4 months. This child’s male cousin
(whose mother is a proven carrier) died of heart disease
at 6 months. Another male cousin was stillborn at term.
There were two further male deaths at 4 months with
cyanosis in the previous generation of this family.
Family 4
The index mother, UPN4, had a brother who died at
6 weeks of age. He was one of male twins, the other
being stillborn. UPN4 went on to have six pregnan-
cies, including two ﬁrst trimester miscarriages. Her ﬁrst
pregnancy produced a male child who died due to con-
gestive cardiac failure with EFE at 7 months of age. Her
third pregnancy resulted in a male stillbirth at 39 weeks’
gestation (although no fetal movements were felt from
33 weeks). No autopsy details are available. Two sub-
sequent pregnancies produced two normal females: the
second son of one of these daughters developed DCM
at 8 months: mutation analysis of DNA from this child
revealed a missense mutation in the TAZ gene (exon 8,
c.626T>A, p.Ile209Asn). This mutation has been previ-
ously reported to cause BTHS and is a highly conserved
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residue. This was conﬁrmed in his mother and the other
daughter of UPN4. The latter has a healthy son and
daughter but is known to have had a ﬁrst trimester mis-
carriage (cause unknown).
Family 5
The ﬁrstborn male to mother UPN5 had intrauterine
growth restriction (IUGR) and was born by spontaneous
vaginal delivery (SVD) at 38 weeks’ gestation weigh-
ing 2.4 kg. He failed to thrive and then died due to
DCM at 7.5 months. Her second born male had IUGR
and was born weighing 2.27 kg at 38 weeks’ gesta-
tion. DCM was present from birth, presenting as feeding
problems and failure to thrive, and led to his death
at 5.5 months. The third pregnancy resulted in a male
who was born at 32.5 weeks’ gestation weighing 2.38 kg
by induced delivery due to fetal distress. Heart failure
was not present at birth but he began to sweat exces-
sively during feeds in the early months of life, showed
delayed motor development and hypotonia, and then
developed DCM at 5 months. Cardiac transplantation
was required at 1.5 years (previously reported in Mangat
et al., 2007). Muscle biopsy performed during investiga-
tion of his heart failure showed lipid storage myopathy,
reduced cytochrome oxidase activity and reduced res-
piratory chain activity of complexes I, III and IV. The
explanted heart also showed reduced activity of com-
plexes I and IV. His motor and speech development were
subsequently delayed and he developed signiﬁcant signs
of myopathy (e.g. unable to do up buttons at 5 years,
positive Gower’s sign at 10 years). He subsequently suf-
fered many infections but is now, at 17 years, well con-
trolled on anti-rejection drugs, prophylactic antibiotics
and granulocyte colony-stimulating factor to alleviate
neutropenia.
BTHS was subsequently proven by identiﬁcation
of a missense mutation in TAZ (exon 2, c.207C>G,
p.His69Gln), which has been previously reported as
causing BTHS and is a highly conserved residue, and
by conﬁrmation of an abnormal MLCL/CL ratio. UPN5
is a proven carrier of this mutation. Her mother lost two
males: the ﬁrst was stillborn at 33 weeks and the second
died at 3 months of suspected fulminant viremia, having
been listless and with feeding difﬁculties for some time
prior to the acute episode. A third male fetus was aborted
after the lady developed a cerebral thrombosis.
Family 6
The second male born to UPN6 by full-term nor-
mal delivery weighing 3.2 kg developed grunting res-
piration, acidosis and hypoglycemia (2.2 mmol/L) at
3 days of age, leading to a diagnosis of DCM. He
was found to be neutropenic with 3-MGC aciduria
and a markedly deranged MLCL/CL ratio. Mutation
analysis revealed a frameshift mutation in TAZ (exon
11; c.837 838delTC, p.Gln280GlyfsX30), which is pre-
dicted to be pathogenic, and was conﬁrmed in his mother
but not in his healthy brother. The brother of UPN6
had failure to thrive, proximal myopathy, motor delay
(walked at 2.5–3 years), recurrent gingivitis and was
reported to have had an ‘abnormal white blood count’
(no details available). He drowned at 14 years of age;
cardiac appearance was reported as normal at post-
mortem. This child’s maternal aunt, who is a proven
mutation heterozygote, has had ﬁve fetal losses, four
early in pregnancy and one at 22 weeks with multiple
malformations.
DISCUSSION
Cardonick et al. (1997) were the ﬁrst authors to con-
clusively demonstrate fetal onset of cardiomyopathy
in BTHS. They reported a mother with a history of
DCM in three brothers. Her ﬁrst child developed asym-
metric IUGR, oligohydramnios and LV dysfunction by
33 weeks’ gestation, having had a normal echocar-
diogram and growth parameters at 21 weeks in utero.
Ventricular dysfunction was still present at birth after
induction at 35 weeks and a diagnosis of BTHS was
conﬁrmed by the ﬁnding of the 3-MGC aciduria and
neutropenia.
Subsequently, Brady et al. (2006) reported an Iranian
ﬁrst cousin couple with an extensive family history of
male infant/toddler death whose ﬁrst male child died at
10 months from a cardiomyopathy. This was believed to
be secondary to a fatty acid oxidation or mitochondrial
oxidative phosphorylation disorder (Brady et al., 2006).
In a subsequent pregnancy, ascites and cardiomegaly
were detected in a male fetus at 32 weeks’ gestation.
That baby was delivered at 33 weeks by LSCS with
growth parameters on the 25 to 50th centiles. Cardiac
ejection fraction was 16%, but there was no excess
organic aciduria and a normal white blood count. After
death, at 12 days, autopsy revealed EFE accompanied
by vacuolization of the subendocardial myocytes and
enlarged mitochondria with disorganized cristae on elec-
tron microscopy of the myocardium. BTHS was con-
ﬁrmed by demonstration of a TAZ mutation.
In the current report, we demonstrate that the fetal
cardiomyopathy associated with proven BTHS may
result in fetal demise or early neonatal death. Two out of
three male pregnancies to UPN1 developed hydrops by
31 weeks and a third was stillborn at the same point
in gestation. This mother’s ﬁrst male fetus was too
macerated to allow reliable autopsy conclusions. Her
second was delivered early—at 34 weeks—because of
hydrops secondary to cardiomyopathy, but this child
still succumbed on day 3 of life despite aggressive
management. The third male pregnancy was terminated
at 31 weeks after the fetus became hydropic; DCM and
diffuse EFE were demonstrated at autopsy. Mutations
were subsequently conﬁrmed in her second and third
male fetuses and UPN1 herself was conﬁrmed as a
carrier of a TAZ mutation. The ﬁrst male fetus born to
UPN2 is thought to have died in utero at 36 to 37 weeks
secondary to DCM with EFE. BTHS was subsequently
proven in her next male pregnancy and UPN2 is a proven
carrier. The male fetus born to UPN3 developed DCM
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at 22 weeks and required urgent delivery at 32 weeks
but died due to cardiac decompensation at 1 week.
The male fetal losses and neonatal deaths in families
4, 5 and 6 were not accompanied by postmortem
examination. However, there is no history of female
miscarriage, stillbirth or neonatal death in these families.
As a TAZ mutation has been conﬁrmed in each of these
families, we suggest that these deaths are highly likely
to have been the result of BTHS.
It is not clear to what extent (if at all) BTHS has
contributed to the ﬁve miscarriages in UPN6, a known
carrier. However, Brady et al. (2006) showed that car-
diomegaly, EFE and subendocardial vacuolization of the
myocytes can be present as early as 18 weeks in utero
in a fetus subsequently proven to have BTHS (who was
aborted electively at that gestation). One of the fetuses
of the sister of UPN6 was spontaneously aborted at
22 weeks’ gestation with multiple malformations. This
may have resulted from an alternative condition, e.g.
chromosome abnormality. However, facial dysmorphism
is recognized in BTHS (Hastings et al., 2009) and we
cannot exclude more signiﬁcant congenital anomalies as
a further manifestation of the disorder.
While cardiac failure per se has undoubtedly con-
tributed to the deaths reported in this and other pub-
lications, it is impossible to rule out the possibility
that ventricular arrhythmia or mitochondrial dysfunction
were signiﬁcant contributory factors. For example, Yen
et al. (2008) observed acute metabolic decompensation
in a 13-day-old child who developed respiratory failure
within 8 h of presenting with lactic acidosis, hyperam-
monemia, hypoglycemia and coagulopathy. Donati et al.
(2006) noted similar metabolic changes in 1- and 3-
day-old babies. We have also seen a child from another
family with proven BTHS who presented with severe
lactic acidosis and hypoglycemia on the ﬁrst day of life
despite absence of cardiac problems (although DCM did
develop by 19 months).
There was no evidence of fetal loss in 13 out of
19 unique families diagnosed in the UK to date. The
mutations in all 19 families were evaluated for evidence
of possible genotype/phenotype correlation. The six
families described in this report are unrelated, and have
unique individual mutations. Four produce amino acid
substitutions within conserved motifs (families UPN1,
3, 4 and 5). One family has a splice site mutation
that would be predicted to result in a truncated protein
(UPN2). One family has a frameshift mutation in the last
exon that results in an extension of the protein (UPN6).
BTHS is known for its phenotypic variability even
within sibships, as highlighted by the cousins described
in Family 3.
It should also be noted that no female carrier of BTHS
has ever been shown to have symptomatology related to
their carrier state. Only 12% of mothers tested do not
carry their son’s mutation; moreover, a limited study
of pedigrees of carrier mothers showed that 8 out of
11 had inherited a de novo mutation from a parent
or grandparent (Kirwin et al., 2007). This means that
fetuses may be lost to such mothers and BTHS would
not be suspected because of the absence of a family
history.
CONCLUSION
We suggest that BTHS is an underrecognized cause
of male fetal demise that may present as a number
of common obstetric scenarios: unexplained pregnancy
loss, hydrops or DCM +/− EFE. MLCL/CL testing
provides a sensitive diagnostic test in fresh or stored
fetal material, or neonatal blood spots, of boys who
have died from problems suggestive of BTHS and for
families where suspicious multiple male fetal/neonatal
deaths have occurred. Mutation testing of the TAZ gene
in families identiﬁed through MLCL/CL testing allows
genetic prenatal diagnosis in subsequent pregnancies.
Unfortunately, there is no abnormality of the MLCL/CL
ratio in heterozygous females so that mothers are not
open to simple screening where fetuses have been lost
previously (Kulik et al., 2008).
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